Skip to main content

Rakovina Therapeutics Inc(RKV-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.130
Day High0.140
Open:0.140
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Rakovina Therapeutics Inc

Select a category then submit the form to load news
GlobeNewswire
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
GlobeNewswire
Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million
GlobeNewswire
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
GlobeNewswire
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
GlobeNewswire
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
GlobeNewswire
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
GlobeNewswire
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
GlobeNewswire
Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
GlobeNewswire
Rakovina Therapeutics Inc. Announces Presentation of Second Abstract at the 2025 Society for Neuro-Oncology Annual Meeting
GlobeNewswire
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
GlobeNewswire
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
GlobeNewswire
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
GlobeNewswire
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
GlobeNewswire
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
GlobeNewswire
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
GlobeNewswire
Rakovina Therapeutics Announces Stock Option Grants
GlobeNewswire
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
AI-generated - The Globe and Mail
Rakovina Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (RKV)
GlobeNewswire
Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
GlobeNewswire
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
GlobeNewswire
Rakovina Therapeutics Announces Share Consolidation Effective Date
AI-generated - The Globe and Mail
Rakovina Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (RKV)
GlobeNewswire
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
GlobeNewswire
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
GlobeNewswire
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
AI-generated - The Globe and Mail
Rakovina Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (RKV)
GlobeNewswire
Rakovina Therapeutics Announces Strategic Private Placement, Convertible Debt Financing, and Share Consolidation to Accelerate US-Focused Growth and AI-Powered Oncology Innovation
GlobeNewswire
Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer
GlobeNewswire
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

Profile

Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a much greater pace than ever before. The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.